1. Switzerland Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Novartis AG

Novartis AG

129.02
CHF
+2.79
(+2.21%)
5.35EPS
23.61P/E
241.71BMarket Cap
Oct 27Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
21.6
22.11
20.97
20.79
18.5
19.88
21.25
21.91
19.6
19.93
22.47
25.63
29.23
29.63
Basic EPS, GAAP
3.76
4.21
7.4
2.82
3.28
5.44
5.12
3.55
10.71
3.19
7.15
5.92
7.21
6.67
Free Cash Flow per Basic Share
4.01
4.33
3.49
3.61
4.4
5.01
4.96
4.86
5.58
5.5
5.64
6.84
7.86
7.83
Dividend per Share
2.5
2.81
2.76
2.72
2.77
3
2.9
3.07
3.28
3.44
3.49
3.78
4.03
4.74
Book Value per Share
30.64
29.5
32.46
31.52
32
34.01
24.49
25.08
30.27
28
22.83
22.3
24.18
21.86
Tangible Book Value per Share
6.38
7.35
4.91
5.27
5.36
1.99
0.07
-4.52
1.74
-0.76
-1.74
-3.86
-4.64
-14.36
Basic Weighted Avg Shares
2,441
2,426
2,403
2,378
2,346
2,319
2,291
2,277
2,243
2,181
2,077
2,018
1,939
1,913
Sales/Revenue/Turnover
52,716
53,634
50,387
49,436
43,404
46,099
48,677
49,898
43,974
43,461
46,660
51,722
56,674
56,693
Operating Margin (%)
20.83
20.68
17.82
16.72
20.05
18.23
18.67
20.35
22.87
18.28
20.94
28.12
31.13
30.17
Depreciation Expense
4,405
4,682
5,471
6,043
4,736
5,211
5,826
6,464
5,597
6,705
8,277
6,069
5,325
5,543
Net Income, GAAP
9,175
10,210
17,783
6,712
7,703
12,611
11,732
8,072
24,021
6,955
14,850
11,941
13,984
12,757
Effective Tax Rate (%)
13.86
12.59
13.6
14.31
17.61
9.19
20.06
18.29
6.62
15.72
6.04
12.47
14.59
17.88
Profit Margin (%)
17.4
19.04
35.29
13.58
17.75
27.36
24.1
16.18
54.63
16
31.83
23.09
24.67
22.5
Working Capital
4,174
10,588
-863
2,722
4,805
5,956
1,240
-3,386
15,510
8,254
4,091
1,012
3,182
-4,397
LT Debt
11,242
13,799
16,327
17,897
23,224
22,470
22,056
27,978
24,523
21,782
20,034
22,934
29,592
39,152
Total Equity
74,472
70,844
77,122
74,891
74,227
78,692
55,551
56,666
67,822
59,423
46,750
44,126
46,549
41,946
Return on Invested Capital (%)
10.14
10.26
7.96
7.02
6.98
7
7.25
8.97
9.42
6.96
11.05
16.64
18.61
16.45
Return on Capital (%)
10.64
11.72
19.29
7.42
8.27
12.61
12.69
9.8
25.61
8.2
19.51
17.27
19.04
16.79
Return on Common Equity (%)
12.79
14.07
24.06
8.84
10.34
16.51
17.5
14.41
38.66
10.95
28.02
26.33
31.01
30.55

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
5,784
7,888
9,862
LT Borrowings
27,935
37,447
37,489
LT Finance Leases
1,657
1,663
1,663
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,908
1,908
1,901
Market Capitalization
263,570
288,883
299,214

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
30,460
26,607
27,351
Cash, Cash Equivalents & STI
11,533
6,977
7,690
Accounts Receivable, Net
8,937
9,386
9,636
Inventories
6,269
6,286
6,220
Total Current Liabilities
27,278
31,374
31,748
Payables & Accruals
9,517
6,129
6,570
ST Debt
5,784
7,888
9,862
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.93%
-2.83%
5.49%
Free Cash Flow
6.52%
6.98%
10.42%
Net Income, GAAP
21.56%
47.51%
17.11%
Sales/Revenue/Turnover
1.5%
2.95%
9.57%
Total Cash Common Dividend
1.72%
2.32%
2.54%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12,120
12,872
13,172
13,558
51,722
2025
13,620
14,836
14,358
13,860
56,674
2026
13,524
14,951
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.32
1.6
1.58
1.42
5.92
2025
1.83
2.07
2.04
1.26
7.21
2026
1.65
1.71
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.55
1.19
- -
- -
3.78
2025
2.71
1.28
- -
- -
4.03
2026
3.25
1.51
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Vasant Narasimhan
Full Time Employees
75,267
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Lichtstrasse 35 Basel BS Switzerland 4056
IPO Date
May 7, 2001
Website
novartis.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Novartis AG is dedicated to the worldwide discovery, advancement, production, and distribution of pioneering healthcare solutions. The enterprise now operates exclusively as an innovative medicines company, having concluded the full divestiture of its Sandoz generics and biosimilars business in October 2023. Its focused efforts encompass key therapeutic areas, including cardiovascular, renal, and metabolic diseases, immunology, neuroscience, and oncology, striving to address significant global patient needs. Within these domains, Novartis offers a suite of advanced therapies such as Kisqali for breast cancer, Kesimpta for multiple sclerosis, Pluvicto for prostate cancer, and Scemblix for chronic myeloid leukemia, in addition to products like Cosentyx, Leqvio, Fabhalta, and Rhapsido for chronic spontaneous urticaria. The company strategically expands its pipeline through acquisitions and partnerships, evidenced by an increased investment and collaboration with Argo Biopharma on RNA interference therapies for cardiovascular conditions, the acquisition of MorphoSys AG to enhance its oncology offerings, and plans for substantial expansion of its manufacturing footprint in the United States. Novartis AG was established in 1996 and is headquartered in Basel, Switzerland.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Novartis: The Sell-Off Creates An Attractive Entry Point

  • seekingalpha.com

    How To Build A $50,000 Dividend Portfolio In Today's Market

  • globenewswire.com

    New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer